Liver Tumor Microenvironment Remodeling Promotes Hepatocellular Carcinoma Progression
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy worldwide. Although radiofrequency ablation (RFA) is widely used for the treatment of early-stage small HCC, its 5-year recurrence rate reaches up to 70%, significantly higher than that of surgical resection, suggesting that the tumor microenvironment (TME) plays a critical role in the progression of residual tumors. Notably, in the context of non-alcoholic fatty liver disease (NAFLD), HCC patients with concurrent fatty liver have an even higher risk of post-RFA recurrence and metastasis, yet the underlying mechanisms remain unclear. Recent studies have shown that extracellular vesicles (EVs), as important mediators of intercellular communication, are abundantly released in the fatty liver microenvironment. By carrying bioactive molecules such as proteins and nucleic acids, EVs remodel the TME and promote HCC cell proliferation, migration, and immune evasion. However, how fatty liver-derived EVs specifically regulate the malignant progression of residual tumors and reshape the immune and metabolic microenvironment under conditions of local thermal stress and ischemia-hypoxia following RFA remains poorly understood. Based on these findings, this project proposes the scientific hypothesis that abnormally released EVs in the fatty liver microenvironment promote post-RFA tumor progression by remodeling the TME and inducing residual HCC cells to acquire a more aggressive phenotype. Elucidating this mechanism is of great significance for understanding the causes of high post-RFA recurrence in the context of fatty liver, identifying potential biomarkers, and developing novel adjuvant therapeutic strategies.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zhe Tang
- 电话号码:18867961022
- 邮箱:8xi@zju.edu.cn
研究联系人备份
- 姓名:Qitao Hu
- 电话号码:13588727974
- 邮箱:22118078@zju.edu.cn
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Clinical data of patients undergoing radiofrequency ablation of liver cancer in the Fourth Affiliated Hospital of Zhejiang University were collected
描述
Inclusion Criteria:
HCC Patient Inclusion Criteria:
Patients with hepatocellular carcinoma (HCC) who meet the following criteria were included: solitary tumor diameter ≤ 5 cm; for multiple tumors, no more than 3 lesions with each tumor diameter ≤ 3 cm, and no evidence of extrahepatic metastasis; Child-Pugh class A or B; absence of refractory ascites or uncorrectable coagulation dysfunction; prothrombin activity > 40% and platelet count > 500,000/L.
Fatty Liver Disease Inclusion Criteria:
Patients were diagnosed with fatty liver disease based on the following criteria: imaging evidence of fatty liver and/or liver biopsy demonstrating ≥5% macrovesicular steatosis of hepatocytes; presence of one or more components of metabolic syndrome; and exclusion of other potential causes of fatty liver, including excessive alcohol consumption, malnutrition, and Wilson's disease.
Exclusion Criteria:
HCC Patient Exclusion Criteria:
Patients were excluded if they presented with vascular invasion or extrahepatic metastasis, severe coagulation disorders, severe cardiopulmonary insufficiency, or uncontrolled hepatic decompensation.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
treatment after RFA
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
progression-free survival
大体时间:1 years after RFA traeatment
|
1 years after RFA traeatment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.